People

Matthew Murrill, MD, PhD

Assistant Clinical Professor
Medicine

Matthew Murrill is an Assistant Professor of Hospital Medicine and an epidemiologist. His overarching research goal is to improve tuberculosis (TB) care, particularly TB prevention, by leveraging epidemiologic and implementation science methods.

Payam Nahid, MD, MPH

Director, UCSF Center for Tuberculosis
Co-Director, UC TRAC
Professor
Medicine

Dr. Nahid is Professor of Medicine in the Division of Pulmonary and Critical Care Medicine. His research includes the conduct of clinical trials and translational research in TB with the goal of improving the care of patients with TB and HIV/TB worldwide.  Dr. Nahid’s research focuses on clinical trials, epidemiological and translational TB research in international settings. He is leads a Vietnam National Tuberculosis Programme-partnered Clinical Trials Unit (CTU) in Hanoi, Vietnam.

Paul Ogongo, PhD

Postdoctoral Scholar
Medicine

Belen Perez Solans, BSPharm, PhD

Postdoctoral Scholar
Bioengineering

Patrick Phillips, PhD, MS, MA

Associate Professor
Co-Director, UC TRAC Clinical & Population Health Science Core
Medicine

The objective of my research is to design, implement, and optimize clinical trials for new treatments for drug-sensitive and drug-resistant tuberculosis in order to deliver safer and more efficacious regimens for patients. A key focus of my research has been to improve the design of TB clinical trials so that regimen development is faster and more efficient. This was motivated by my PhD thesis evaluating surrogate endpoints for TB trials, and has grown in a number of areas through the various collaborations and consortia that I contribute to.

Sarah Puryear, MD, MPH

ASST ADJ PROF-HCOMP

My tuberculosis-related research focuses on the intersections of alcohol, HIV, and TB in sub-Saharan Africa. My current work is seeking to establish associations between alcohol use levels and tuberculosis infection incidence and prevalence among people living with HIV in order to inform TB prevention efforts. Clinically, I attend on the HIV/Infectious disease inpatient consult service at ZSFG and care for patients at the Ward 86 Positive Health Practice.

 

Mike Reid, MD, MPH, MA

Associate Professor
Epidemiology & Biostatistics

Mike currently serves as the Chief Science Officer for PEPFAR in the Bureau of Global Health Security and Diplomacy in the US State Department. He also serves as Associate Director of the Center for Global Health Diplomacy, Delivery and Economics. He is an HIV clinician and sees patients at San Francisco General Hospital.

George Rutherford, MD, MA

Professor
Epidemiology & Biostatistics

My research interests are the epidemiology and prevention of infectious and tropical diseases of public health importance, both internationally and domestically, with a primary focus on HIV and AIDS. My work is funded primarily by the Centers for Disease Control and Prevention through the Presidential Emergency Plan for AIDS Relief. I also have smaller projects dealing with the epidemiology of tuberculosis in California, the prevention of childhood injury, immunizations and bioterrorism. I am a member of the AIDS Research Institute's Executive Committee.

Rada Savic, PhD

Co-Director, UCSF Center for Tuberculosis
Professor
Bioengineering

With an emphasis on TB therapeutics, my research uses computational methods to study the dynamic interplay between disease progression, drug and biomarker response across relevant scales (molecule, cell, tissue, organ & whole body) in order to determine causal links underlying variability in (safety and efficacy) clinical outcomes.

Jason Sello, PhD

Professor
Pharmaceutical Chemistry

Priya Shete, MD, MPH

Co-Director, UC TRAC Clinical & Population Health Science Core
Associate Professor
Medicine

I focus on two main areas of TB research: 1) Implementation and operational research to improve programmatic outcomes of TB diagnostic and treatment care using evidence-based guidelines; and 2) Social protection research aimed at improving patient and public health outcomes by implementing social protection interventions to overcome socioeconomic barriers to TB care and evaluating both economic and TB outcomes of these approaches.

Sara Suliman, PhD, MPH

Assistant Prof In Residence
Medicine

Tuberculosis (TB) disease, caused by infection with the intracellular pathogen Mycobacterium tuberculosis (Mtb) remains a leading cause of mortality globally. Interestingly, only 5-10% of Mtb-exposed individuals are estimated to develop active TB in their lifetime, thus posing host-specific factors as mediators of risk of progression to disease. These host factors include several defects in innate and adaptive immunity, metabolic dysregulation, co-infections and comorbidities, and genetic polymorphisms that could mediate susceptibility to TB disease.

Pages